Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7685725 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7688030 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7689661 | 0.82 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6188593 | 0.82 | CHRNB4 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4012050 | 0.80 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7679281 | 0.80 | CHRNA4 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7679285 | 0.79 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7689713 | 0.79 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4013791 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5372757 | 0.79 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | CHRNB2 1123/4885CHRNA4 1314/4885CHRNB4 1088/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CHRNB2 1123/4885CHRNA4 1314/4885CHRNB4 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.